Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20124357 | 0.93 | SLC5A2 (0.46) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13445813 | 0.92 | SLC5A2 (0.39) | SLC5A2SLC5A1TSHRADRA2ASLC5A11 | |
| SCHEMBL48256 | 0.91 | HSD17B10 (0.38) | SLC5A2SLC5A1TSHR | |
| SCHEMBL13823171 | 0.90 | SLC5A2 (0.37) | SLC5A2SLC5A1TSHR | |
| SCHEMBL13823170 | 0.89 | SLC5A2 (0.40) | SLC5A2SLC5A1TSHR | |
| SCHEMBL13445815 | 0.84 | SLC5A2 (0.36) | SLC5A2SLC5A1TSHR | |
| SCHEMBL48102 | 0.82 | SLC5A2 (0.51) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL49843 | 0.82 | SLC5A2 (0.51) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL499803 | 0.80 | TSHR (0.57) | SLC5A2SLC5A1TSHRADRA2ASLC5A11 | |
| SCHEMBL3680813 | 0.77 | HSD17B10 (0.39) | SLC5A2TSHRADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312944-B1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2230907-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| WO-2009076550-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076550-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885TSHR 3655/4885 |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A4 | SLC5A2 2/4885SLC5A1 1/4885TSHR 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.